Wells Fargo raised the firm’s price target on Gilead (GILD) to $145 from $140 and keeps an Overweight rating on the shares. The firm thinks the company’s Q3 was strong as Yeztugo real demand was much higher than expectations and HIV strength more than offset cell therapy weakness for guide. Wells continues to see Gilead as its top pick and thinks there is enough to like at 13-times 2026 EPS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences Reports Strong Q3 2025 Results
- Gilead Sciences: Strong Financial Performance and Promising Growth Prospects Justify Buy Rating
- Closing Bell Movers: Amazon soars to all-time highs on earnings
- Gilead reports Q3 adjusted EPS $2.47, consensus $2.14
- Gilead narrows FY25 EPS view to $8.05-$8.25 from $7.95-$8.25